U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07313436) titled 'Extended Release Protein Dosing' on Dec. 03, 2025.
Brief Summary: The overall goal of this study is to determine the minimum dose required to elicit measurable elevation of plasma essential amino acid levels 12 hours after consuming VitaKey's extended release protein technology. The results of this study will be used to set a dose for future protein clinical studies.
Study Start Date: Nov. 17, 2025
Study Type: INTERVENTIONAL
Condition:
Nutrition
Intervention:
OTHER: Extended release nutritional protein
Participants will consume a beverage with extended release protein.
OTHER: Control
Participants will consume a beverage with...